Evaluating the Effects of Cannabis Use and Circulating Cannabinoids on Tumor Infiltrating Lymphocytes in Malignant Melanoma
Protocol #22-1132
Location: Highlands Ranch Hospital - CU Med Clinics, University of Colorado Hospital
|
Development and Validation of an Ancillary Diagnostic Test for Mycosis Fungoides (SIGNAL-MF)
Protocol #22-1708
Location: Department Specific Free Standing Clinic, University of Colorado Hospital
|
S2101: Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726)
(BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study
Protocol #22-2225
Location: Rocky Mountain Regional VA Medical Center
|
Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants with Advanced Solid Tumors
Protocol #22-1490
Location: University of Colorado Hospital
|
A PHASE 1/2, OPEN LABEL, DOSE ESCALATION AND EXPANSION STUDY OF TAC-001 IN PATIENTS WITH SELECT ADVANCED OR METASTATIC SOLID TUMORS
Protocol #22-1188
Location: CTRC Inpatient, University of Colorado Hospital
|
A Phase 1/2, Open-Label Study of the Pressure-Enabled Hepatic Artery Infusion of SD-101, a TLR9 Agonist, Alone or in Combination with Intravenous Checkpoint Blockade in Adults with Metastatic Uveal Melanoma
Protocol #21-3200
Location: CTRC Inpatient, Outpatient CTRC, University of Colorado Hospital
|
S2000 - A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab Vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases
Protocol #21-2584
Location: University of Colorado Hospital
|
A First-in-Human, Two-Part, Open-Label, Phase I/II Study of DSP107 in Subjects with Advanced Solid Tumors Including a Dose-Escalation Safety Study (Part 1) and Preliminary Efficacy Assessment of DSP107 as Monotherapy and in Combination with Atezolizumab (Part 2)
Part 1 of the study is open to all solid tumors. Part 2 of the study will evaluate the safety, tolerability and preliminary efficacy of
DSP107, administered either as monotherapy or in combination with atezolizumab.
The study will enrol subjects with NSCLC that is wildtype for actionable...
Protocol #20-1690
Location: University of Colorado Hospital
|
AN OPEN-LABEL, MULTICENTER, PHASE 1B/2 STUDY OF RP1 IN SOLID ORGAN TRANSPLANT RECIPIENTS WITH ADVANCED CUTANEOUS MALIGNANCIES
Protocol #19-2987
Location: CTRC Inpatient, Outpatient CTRC, University of Colorado Hospital
|
Financial Burden Associated with Retirement among Cancer Survivors
Protocol #19-1419
|
Evaluation of Sun Protection Education using the Reveal Imager Photo-aging and the SPA Questionnaire
Protocol #17-2424
Location: Department Specific Free Standing Clinic, University of Colorado Cancer Center, University of Colorado Hospital
|
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Protocol #18-6055
Location: Greeley Campus, Harmony Campus, Medical Center of the Rockies, Poudre Valley Hospital
|
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Protocol #22-0130
Location: CTRC Inpatient, Outpatient CTRC, University of Colorado Hospital
|
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open-label Phase IA/IB Study
Protocol #22-0094
Location: CTRC Inpatient, University of Colorado Hospital
|
051/02 A Phase I/II Study of Pembrolizumab (MK-3475) in Children with Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)
Protocol #16-0064
Location: Childrens Hospital Colorado
|
Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer (ORIEN)
Protocol #15-1110
Location: Cherry Creek Medical Center, Highlands Ranch Hospital, Memorial Hospital Central, Memorial Hospital North, Poudre Valley Hospital, University of Colorado Hospital
|
A Phase II, Multicenter, Single-Arm Clinical Trial of Definitive Radiotherapy And CeMiPlimAb-Rwlc ImmunoTherapy for Locally Advanced, Unresectable Cutaneous Squamous Cell Carcinoma: RAMPART
Protocol #22-1922
Location: Highlands Ranch Hospital, University of Colorado Hospital
|
